Acrylic lenses produce virtually no PCO

Article

The new acrylic *Acri.Lyc 356 (*Acri.Tec) diffractive intraocular lens (IOL) produces practically no posterior capsule opacification (PCO) compared with its silicone counterpart.

The new acrylic *Acri.Lyc 356 (*Acri.Tec) diffractive intraocular lens (IOL) produces practically no posterior capsule opacification (PCO) compared with its silicone counterpart, according to Filippo Simona from the LaserVis Refractive Centre, Locarno, Switzerland.

In a prospective, non-randomized pilot study, 116 eyes of 78 patients with senile cataract underwent phacoemulsification and implantation of the acylic *Acri.Lyc 356 (35 eyes) or the silicone *Acri.Tec 737 (81 eyes).

The results showed that both lenses provided both good near and distance visual acuity, however, the acrylic lens produced hardly any PCO, just 1% compared with 14% in the silicone group.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.